|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001128,
umls-concept:C0086222,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0442027,
umls-concept:C0470187,
umls-concept:C0597357,
umls-concept:C1333711,
umls-concept:C1527415,
umls-concept:C1705733,
umls-concept:C1706579
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-3-9
|
|
pubmed:abstractText |
Small molecule mGluR1 enhancers, which are 9H-xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides, have been previously reported. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides with improved pharmacokinetic properties have been designed and synthesized as useful pharmacological tools for the study of the physiological roles mediated by mGlu1 receptors. The synthesis and the structure-activity relationship of this class of positive allosteric modulators of mGlu1 receptors will be discussed in detail.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1666-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19233648-Administration, Oral,
pubmed-meshheading:19233648-Amides,
pubmed-meshheading:19233648-Animals,
pubmed-meshheading:19233648-CHO Cells,
pubmed-meshheading:19233648-Chemistry, Pharmaceutical,
pubmed-meshheading:19233648-Cricetinae,
pubmed-meshheading:19233648-Cricetulus,
pubmed-meshheading:19233648-Drug Design,
pubmed-meshheading:19233648-Electrophysiology,
pubmed-meshheading:19233648-Humans,
pubmed-meshheading:19233648-Models, Chemical,
pubmed-meshheading:19233648-Molecular Structure,
pubmed-meshheading:19233648-Rats,
pubmed-meshheading:19233648-Receptors, Metabotropic Glutamate,
pubmed-meshheading:19233648-Structure-Activity Relationship
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers.
|
|
pubmed:affiliation |
Pharma Division, Discovery Research, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article
|
